University of Tübingen at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
University of Tübingen brings 3 presentations to ESGCT 2026 in Hamburg. Its contributions span antisense oligonucleotide medicines and gene editing for severe congenital neutropenia, including the safety questions that arise on the way to the clinic. It also offers organ-on-chip systems as a human-relevant way to test gene therapies.
| Organization | ESGCT 2026 Attendance |
|---|---|
University of Tübingen Tübingen, Germany | |
Public research university in Tübingen, Germany. | Workshop Tue Oct 27 10:20am–10:45am Antisense Oligonucleotides: Programmable Medicines Beyond Gene Therapy RNA and oligonucleotide therapies Talk Thu Oct 29 9:00am–10:30am Gene editing for severe congenital neutropenia: preclinical efficacy and the safety considerations for clinical translation. Gene and epigenome editingRare and inherited disease Poster Thu Oct 29 2:00pm–4:00pm Organ-on-chip as human-relevant in vitro platform for gene therapy research and development Chair Thu Oct 29 4:00pm–6:00pm SESSION 9a: CNS & sensory II Rare and inherited disease |
Instantly find 20 buyers from University of Tübingen
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction